BioShield II Patent Extensions Will Increase Drug Costs, GPhA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The Generic Pharmaceuticals Association supports the overall goals of the bill but claims product exclusivity extensions will needlessly inflate pharmaceutical costs. The association will testify before the Oct. 6 joint Senate Judiciary/Health Committee hearing.
You may also be interested in...
GPhA's 2005 Priorities Include Generic Biologics, Biodefense Incentives
The Generic Pharmaceutical Association will continue to push for an approval pathway for generic biologics and work against "authorized" generics and patent term exclusivity extensions contained in biodefense legislation, President Jaeger tells group's annual meeting.
GPhA's 2005 Priorities Include Generic Biologics, Biodefense Incentives
The Generic Pharmaceutical Association will continue to push for an approval pathway for generic biologics and work against "authorized" generics and patent term exclusivity extensions contained in biodefense legislation, President Jaeger tells group's annual meeting.
"BioShield II" Hearing Reveals Continued Division On IP Incentives
GPhA should provide more input on its concerns over intellectual property protections in the bill, Sen. Enzi says. Though R&D incentives are needed, a "wild card" exclusivity provision could allow unfair patent extensions, Sen. Schumer argues.